Tocilizumab for giant cell arteritis: what is optimal?

Mahmut Kaymakci; Kenneth J. Warrington

doi:10.55563/clinexprheumatol/u5tnbs

Tocilizumab for giant cell arteritis: what is optimal?

Rheumatology

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	777-779
Number of pages	3
Journal	Clinical and experimental rheumatology
Volume	41
Issue number	4
DOIs	https://doi.org/10.55563/clinexprheumatol/u5tnbs
State	Published - Apr 1 2023

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.55563/clinexprheumatol/u5tnbs

Cite this

@article{b52d13947dec4d7cba4bfb7ff66e5fa5,

title = "Tocilizumab for giant cell arteritis: what is optimal?",

author = "Mahmut Kaymakci and Warrington, {Kenneth J.}",

year = "2023",

month = apr,

day = "1",

doi = "10.55563/clinexprheumatol/u5tnbs",

language = "English (US)",

volume = "41",

pages = "777--779",

journal = "Clinical and Experimental Rheumatology",

issn = "0392-856X",

publisher = "Clinical and Experimental Rheumatology S.A.S.",

number = "4",

}

TY - JOUR

T1 - Tocilizumab for giant cell arteritis

T2 - what is optimal?

AU - Kaymakci, Mahmut

AU - Warrington, Kenneth J.

PY - 2023/4/1

Y1 - 2023/4/1

UR - http://www.scopus.com/inward/record.url?scp=85152973007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152973007&partnerID=8YFLogxK

U2 - 10.55563/clinexprheumatol/u5tnbs

DO - 10.55563/clinexprheumatol/u5tnbs

M3 - Editorial

C2 - 36995336

AN - SCOPUS:85152973007

SN - 0392-856X

VL - 41

SP - 777

EP - 779

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

IS - 4

ER -

Tocilizumab for giant cell arteritis: what is optimal?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this